Updated November 2026
The SSP is a publicly available summary of the main safety and performance information for certain in vitro diagnostic medical devices, required under Regulation (EU) 2017/746 (IVDR).
This guide explains what SSP means, which devices require one, what information it contains, and how it relates to performance evaluation, post-market surveillance and the European database on medical devices, EUDAMED.

In this guide
- What is an SSP?
- Which devices require an SSP?
- What information does it contain?
- Professional users and devices for self-testing
- Who prepares and validates it?
- Updates and post-market surveillance
- SSP and EUDAMED
What is an SSP?
SSP stands for Summary of Safety and Performance. Its main legal basis is Article 29 of Regulation (EU) 2017/746.
The document provides public access to information about the in vitro diagnostic medical device and the evidence supporting its safety and performance.
The information in the SSP is drawn from the device’s technical documentation, including documents relating to performance evaluation, risk management and post-market surveillance.
SSP does not replace the instructions for use, which remain the main document for information on the safe use of the device. Nor is it intended to provide individual diagnostic or therapeutic advice.
Which devices require an SSP?
Article 29 of the IVDR requires an SSP for class C and class D in vitro diagnostic medical devices, other than devices for performance studies.
The requirement does not therefore extend to every device whose conformity assessment involves a notified body. It applies to the classes expressly identified in the Regulation.
A distinction applies to legacy devices, which continue to be placed on the market under the transitional provisions of Article 110 of the IVDR, subject to the conditions set out in the Regulation.
MDCG 2022-8 clarifies that the SSP requirement under Article 29 does not apply to these legacy devices.
Distinguishing between IVDR devices and devices benefiting from the transitional provisions is therefore important when determining whether an SSP is required.
What information does it contain?
Article 29(2) sets out the information to be included in the SSP.
This includes:
- identification of the device and the manufacturer, including the Basic UDI-DI, the basic device identifier, and the single registration number (SRN), if already issued;
- the intended purpose, indications, contraindications and target populations;
- a description of the device, including any previous generations or variants and the differences between them, together with any relevant accessories, other devices and products intended to be used in combination with it;
- references to any harmonised standards and common specifications applied;
- a summary of the performance evaluation and relevant information on post-market performance follow-up (PMPF);
- information on the metrological traceability of assigned values;
- the suggested profile and training for users;
- information on any residual risks and any undesirable effects, warnings and precautions.
Performance evaluation, addressed in Article 56 and Annex XIII of the IVDR, covers the device’s scientific validity, analytical performance and clinical performance.
MDCG 2022-9 rev.1 provides a structured template for presenting SSP information, including data from performance studies and ongoing or planned PMPF activities.
For companion diagnostics, the template includes specific information on the relationship between the test and the associated medicinal product.
The recommendations in the MDCG template should be distinguished from the requirements laid down in the Regulation itself.
Professional users and devices for self-testing
The SSP must be clear to the intended users and, where relevant, patients.
MDCG 2022-9 rev.1 distinguishes between devices not intended for self-testing and devices intended for self-testing.
For devices not intended for self-testing, the summary is primarily intended for professional users. Where the manufacturer considers information for patients relevant, the MDCG template provides for an additional part written in language that is clear to lay persons.
For devices intended for self-testing, the SSP should be clear to patients and lay persons, taking account of the characteristics of the target population.
Adapting the presentation to the audience does not change the need for accuracy and consistency with the scientific evidence and the device documentation.
Who prepares and validates it?
The manufacturer draws up the SSP using the device’s technical documentation and submits the draft to the notified body involved in the conformity assessment.
The notified body validates the summary after checking that the required information is included, accurately presented and consistent with the relevant technical documentation.
For class C devices, MDCG 2022-9 rev.1 describes specific arrangements linked to the sampling of technical documentation.
According to the guidance, where the relevant certificate covers more than one class C device, at least one draft SSP should be validated against the technical documentation during the initial conformity assessment, before the certificate is issued.
Drafts not validated at the initial conformity assessment should be validated against the technical documentation at least once during the period of validity of the certificate.
These arrangements concern the process and timing of validation. They do not change the scope of Article 29.
Updates and post-market surveillance
Article 56(6) of the IVDR requires the SSP to be updated as soon as possible, where necessary.
Updates to the performance evaluation report and data collected after the device has been placed on the market may affect the information included in the summary.
Relevant processes and documents include:
- post-market surveillance (PMS), through which information on the device is collected and analysed after it has been placed on the market;
- post-market performance follow-up (PMPF), involving the ongoing collection and evaluation of data relevant to the device’s performance;
- the periodic safety update report (PSUR), required under Article 81 of the IVDR for class C and class D devices.
MDCG 2022-9 rev.1 identifies updates to the PMPF evaluation report and the PSUR as factors to consider when determining whether the SSP also needs to be updated.
A review of the summary does not necessarily require changes to the text. The content needs to be updated when new information affects the accuracy or completeness of the published information.
Keeping the SSP up to date is therefore part of the wider process of ongoing performance evaluation and post-market surveillance.
SSP and EUDAMED
The IVDR requires the SSP to be made available to the public through EUDAMED, the European database on medical devices.
Article 29 also requires the manufacturer to indicate on the label or in the instructions for use where the summary is available.
Use of the first four EUDAMED modules has been mandatory since 28 May 2026:
- Actor registration;
- UDI/Devices registration;
- Notified Bodies & Certificates;
- Market Surveillance.
Mandatory use forms part of the gradual roll-out introduced by Regulation (EU) 2024/1860, which includes transitional provisions for specific obligations.
For SSP management, Article 29 of the IVDR provides for the notified body to upload the validated summary to EUDAMED.
However, MDCG 2026-4 rev.1, originally published in June 2026 and updated by revision 1 in October 2026, describes the planned transfer of the task of uploading SSPs to manufacturers, while retaining the notified body’s role in validation.
Under the new arrangements, the manufacturer would upload the master version of the validated SSP and its translations, while the notified body would confirm validation using the relevant system functionality.
The change depends on the availability of the new functionality in the EUDAMED Production environment. MDCG 2026-4 rev.1 indicates a planned deployment in December 2026.
MDCG 2026-4 rev.1 also describes an interim arrangement under which the notified body continues to upload the master version of the SSP until the new functionality is fully available.
For devices placed on the market before mandatory use of the UDI/Devices module and for which an SSP is required, MDCG 2026-4 rev.1 indicates that manufacturers should upload the relevant SSPs as soon as possible, and no later than 27 March 2027, coordinating their activities with the notified bodies.
MDCG 2026-4 rev.1 is a non-legally binding position paper and should be read alongside the applicable legal provisions. Operational arrangements for managing documents need to take account of the functionality actually available and the current EUDAMED documentation.
Why this guide is not an SSP template
This page explains the purpose and general regulatory framework of the SSP. It does not provide a completed template or a summary for a particular in vitro diagnostic medical device.
The information included in an SSP depends on the device’s characteristics, intended purpose, intended users, and the scientific evidence and data supporting its performance.
This guide is therefore for information only and does not establish procedures for preparing, validating or updating an SSP for an individual product.
Informational note
This guide is published for informational purposes only and does not constitute regulatory, legal, technical or professional advice.
The information is based on publicly available sources and was checked as of the publication or last update date of this page. It may therefore not reflect subsequent changes or developments.
For assessments relating to specific cases, it is necessary to refer to the official texts, the updated documentation of the competent authorities and, where appropriate, qualified professionals.
Official sources
- Regulation (EU) 2017/746 — EUR-Lex: in particular Articles 29, 56, 78, 81 and 110, and Annex XIII.
- MDCG 2022-9 rev.1 — Summary of safety and performance template
- MDCG 2022-8 — Application of IVDR requirements to legacy devices
- MDCG 2026-4 rev.1 — Management of SS(C)P in EUDAMED after mandatory use
- European Commission — EUDAMED overview
Share this guide
If you find this guide useful, you can share it with other professionals interested in IVDR.
Want to stay updated on MDR and IVDR?
Subscribe to MDN – Medical Device News for free.
Subscribers receive the newsletter by email every Monday, one week before publication on the website.
Related resources
- What is the IVDR?
- IVDR Notified Bodies
- IVDR Codes
- IVDR Classification Rules
- IVDR Harmonised Standards
- IVDR Post-Market Surveillance
- Performance Evaluation
- UDI and Basic UDI-DI
Copyright and reuse
© Simone Ronco. Unless otherwise stated, the editorial content of this guide is an original work.
Short excerpts may be quoted with attribution to the author and a link to the original page.
Full reproduction, translation, adaptation or commercial use of the content requires prior written permission.